Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05741307
Other study ID # APHP220842
Secondary ID 2022-A01509-34
Status Recruiting
Phase N/A
First received
Last updated
Start date September 4, 2023
Est. completion date April 2025

Study information

Verified date February 2024
Source Assistance Publique - Hôpitaux de Paris
Contact Catherine Grosmaitre, PhD
Phone 1 44 49 45 67
Email catherine.grosmaitre@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The prevalence of Attention Deficit/ Hyperactivity (ADHD) varies between 3 and 10% depending on the studies. Comorbidities are frequently associated, in particular anxiety disorders. School, social and family consequences of ADHD can be major, especially in the presence of a comorbidity. The study goal is to evaluate, through questionnaires, the effect of self-hypnosis via a smartphone application, on the symptoms of inattention and anxiety in children with ADHD in addition to their treatment by methylphenidate. Parents and children complete the study questionnaires four times. - T0: at inclusion - T1 (T0+6 weeks): after 6 weeks of using the self-hypnosis application 5 days out of 7 for group 1 in parallel with the usual treatment / after 6 weeks of usual treatment for the group 2 - T2 (T0+8 weeks): after a wash-out period of 2 weeks (usual treatment only) for both groups - T3 (T0+14 weeks): after 6 weeks of use of the self-hypnosis application 5 days out of 7 for group 2 in parallel with the usual treatment / after 8 weeks of usual treatment for the group 1, following the 6 weeks of use of the application.


Description:

The prevalence of Attention Deficit/ Hyperactivity (ADHD) varies between 3 and 10% depending on the studies. Comorbidities are frequently associated, in particular anxiety disorders. School, social and family consequences of ADHD can be major especially in the presence of a comorbidity. The management of ADHD requires an effective multimodal approach to attention disorders and comorbid disorders. In France, the Haute Autorité de Santé recommends the combination of drug treatment with methylphenidate (as a second line or, for serious cases, from the first line) and a non-drug treatment such as behavioral therapies, cognitive remediation and psycho-educational support. As part of this project, and more generally for the care of young ADHD patients, it is interesting to target a method that can be deployed in a relatively controlled way in addition to other non-drug measures and without contradicting them. Hypnosis is a technique that is already widely used in the treatment of pain. In the field of mental health, the clinical use of hypnosis is a relevant strategy to support self-regulation capacities in anxious children. Indeed, this technique offers an easily accessible experience of reducing arousal and dissociating internal physical sensations and perceptions, while promoting attentional focus towards the examination of new possibilities. The repeated use of self-hypnosis incorporating imaginary exposure facilitates the feeling of capacity for action ("empowerment") in the face of anxiety-provoking elements, reduces hyper-reactivity, and leads to the control of physiological reactivity. In France, it is difficult for families to find structures for the care and monitoring of child's ADHD. The lack of speech therapists, the waiting list in public medical institution, the cost of follow-up by private psychologists, the lack of specialized structures are obstacles to care and increase the risk of pejorative evolution. In this context, the use at home by the child of a digitized self-hypnosis tool has all its interest. The objectives of the study are to evaluate, through questionnaires, the effect of self-hypnosis via a smartphone application, on the symptoms of inattention and anxiety in children with ADHD in addition to taking classical pharmacological load by methylphenidate. Parents and children complete the study questionnaires four times. - T0: at inclusion - T1 (T0+6 weeks): after 6 weeks of using the self-hypnosis application 5 days out of 7 for group 1 in parallel with the usual treatment / after 6 weeks of usual treatment for the group 2 - T2 (T0+8 weeks): after a wash-out period of 2 weeks (usual treatment only) for both groups - T3 (T0+14 weeks): after 6 weeks of use of the self-hypnosis application 5 days out of 7 for group 2 in parallel with the usual treatment / after 8 weeks of usual treatment for the group 1, following the 6 weeks of use of the application.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date April 2025
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender All
Age group 7 Years to 12 Years
Eligibility Inclusion Criteria: - Patient of French mother tongue, aged 7 to 12 with a diagnosis of ADHD made by a child psychiatrist or neuropediatrician according to DSM-5 criteria - Patient treated with methylphenidate and followed by the child psychiatry department - Reference Center for Language and Learning Disorders of the Necker Enfants Malades Hospital - Information and consent of holders of parental authority and of the patient Exclusion Criteria: - Presence of an intellectual disability - Presence of an autism spectrum disorder

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Self-hypnosis application
The Hypnotidoo application offers screenless self-hypnosis sessions for 5-12 year olds. Each session lasts 6 to 8 minutes and focuses on one of the following themes: stress and anxiety, sleep, daily troubles and discomforts, hypersensitivity, hyperactivity and difficulty concentrating, self-confidence, difficult life events, anger. Each session begins with breathing and refocusing work, followed by self-hypnosis through stories and metaphors suitable for children. The application will be used by patients in the context of research for 6 weeks, 5 days out of 7 in parallel with the usual treatment.
Other:
Questionnaires
Before and after (at T0, T1, T2 and T3) the 6-week period of use of the application and a wash-out period of 2 weeks (= usual treatment only), self- and hetero-questionnaires which constitute the gold standard for evaluating the symptoms of inattention and anxiety are proposed: Conners III, Child Behavior Checklist (CBCL) and Revised-Children's Manifest Anxiety Scale (R-CMAS). T0: inclusion T1: 6 weeks after T0 (inclusion) T2: 2 weeks after T1 T3: 6 weeks after T2

Locations

Country Name City State
France Hôpital Necker-Enfants Malades Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

References & Publications (5)

Hiltunen, S., Virta, M., Salakari, A., Antila, M., Chydenius, E., Kaski, M., … Partinen, M. (2014). Better long-term outcome for hypnotherapy than for CBT in adults with ADHD: Results of a six-month follow-up. Contemporary Hypnosis and Integrative Therapy, 30, 118-134.

Kaiser P. Childhood anxiety and psychophysiological reactivity: hypnosis to build discrimination and self-regulation skills. Am J Clin Hypn. 2014 Apr;56(4):343-67. doi: 10.1080/00029157.2014.884487. — View Citation

Landier W, Tse AM. Use of complementary and alternative medical interventions for the management of procedure-related pain, anxiety, and distress in pediatric oncology: an integrative review. J Pediatr Nurs. 2010 Dec;25(6):566-79. doi: 10.1016/j.pedn.2010.01.009. Epub 2010 Mar 12. — View Citation

Richardson J, Smith JE, McCall G, Pilkington K. Hypnosis for procedure-related pain and distress in pediatric cancer patients: a systematic review of effectiveness and methodology related to hypnosis interventions. J Pain Symptom Manage. 2006 Jan;31(1):70-84. doi: 10.1016/j.jpainsymman.2005.06.010. — View Citation

Virta, M., Salakari, A., Antila, M., Chydenius, E., Partinen, M., Kaski, M., & Iivanainen, M. (2010). Hypnotherapy for adults with attention deficit hyperactivity disorder: A randomized controlled study. Contemporary Hypnosis, 27, 5-18.

Outcome

Type Measure Description Time frame Safety issue
Primary Change in severity of attention deficit The severity of attention deficit is assessed with the Conners 3 questionnary. It provide information's for information for 11 scales and includes 110 questions. Our research will focus on the T-score of inattention scale (mean=100, standard deviation=10). The higher the score is, the severed the symptom is. The change of the inattention scale T-score from base line at 6 weeks and 14 weeks will be used as primary outcome. Day 0, 6 weeks, 8 weeks, 14 weeks
Secondary Change in severity of anxiety with a self-questionnaire Assessment with the Revised-Children's Manifest Anxiety Scale (R-CMAS). The R-CMAS is a self-questionnaire of 28 anxiety items and 9 lying items. It provides scores for Total Anxiety and 4 subscales: Physiological Anxiety, Worry/Sensitivity, Social Concerns/Concentration, Lie Scale. The notation is binary: true/false. Our research will focus on anxiety total T-score (mean at 50, standard deviation at 10). The higher the T-Score is, the severed the symptom is. The change of the anxiety total R-CMAS T-score from base line at 6 weeks and 14 weeks will be used as seondary outcome. Day 0, 6 weeks, 8 weeks, 14 weeks
Secondary Change in severity of anxiety with a hetero-questionnaire Assessment with the Child Behavior Checklist inventory (CBCL). The CBCL provides information on 6 scales: Anxious/Depressed, Withdrawn/Depressed, Somatic Complaints, Social Problems, Thought Problems, Attention Problems, Rule-Breaking Behavior, and Aggressive Behavior. It includes 113 questions, noted from 0 to 2, depending on the presence of each symptom. Our research will focus on the T-score of the anxiety/Depressed scale (mean at 50, standard deviation at 10). The higher the T-Score is, the severed the symptom is. The change of the inattention scale T-score of the CBCL from base line at 6 weeks and 14 weeks will be used as seondary outcome. Day 0, 6 weeks, 8 weeks, 14 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06133231 - Optimizing Research With Diverse Families N/A
Completed NCT02286349 - Non Invasive Brain Stimulation Effects on Attentional Performance in ADHD Adults N/A
Completed NCT00214981 - Evaluate the Safety and Efficacy of Modafinil in Children and Adolescents With ADHD Phase 3
Active, not recruiting NCT04189536 - An SMS Intervention to Improve Adherence to Stimulant Medications in Adults With ADHD N/A
Recruiting NCT02433145 - Explore the Association Between Neuropsychological Functions and ADHD Diagnosis and Comorbid Using Longitudinal Study in Preschool Children N/A
Completed NCT01263548 - To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of ADHD in Euthymic Adults With Bipolar I/II Disorder N/A
Completed NCT01275378 - Comparative Effectiveness Research for Two Medical Home Models for Attention Deficit Hyperactivity Disorder N/A
Completed NCT02728011 - Pilot Trial Comparing Computerised Cognitive Exercises to Tetris in Adolescents With ADHD N/A
Active, not recruiting NCT00863499 - International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder Phase 4
Not yet recruiting NCT00945971 - Exercise Effects in Children With Attention Deficit Hyperactivity Disorder N/A
Active, not recruiting NCT04999982 - Pilot Testing PREschooler Care, Community Resources, Advocacy, Referral, Education (PRE-CARE) N/A
Completed NCT01259492 - Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD) Phase 3
Recruiting NCT05721235 - A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD Phase 4
Active, not recruiting NCT04189575 - A Text Messaging (SMS) Intervention to Improve Adherence to Stimulant Medication in Adults With ADHD in the Primary Care Setting N/A
Active, not recruiting NCT05685732 - An Efficacy and Safety Study w/ Azstarys® in Children With ADHD Phase 4
Completed NCT02558790 - L-Threonic Acid Magnesium Salt (L-TAMS) in ADHD Phase 2
Recruiting NCT02205268 - Near Infrared Spectroscopy Neurofeedback Training for ADHD N/A
Recruiting NCT00946582 - The Therapeutic Effects of Barkley's Parenting Management Program for Taiwanese School-Aged Children With Attention Deficit/Hyperactivity Disorder (ADHD) Phase 1
Completed NCT00267605 - Strongest Families (Formerly Family Help Program): Pediatric Attention Deficit/Hyperactivity Disorder Phase 2
Recruiting NCT02017483 - Explore the Association Between the Emotion Recognition and the Attention Processing Under the Emotional Stimuli in ADHD N/A